OMT Announces OmniRat™ Collaboration with CNA Development LLC
News Dec 24, 2012
Open Monoclonal Technology, Inc. (OMT) has announced a discovery collaboration with CNA Development LLC, an affiliate of Janssen Pharmaceuticals, Inc.
OMT will employ its OmniRat™ transgenic animal platform to generate human antibodies with great specificity, affinity and manufacturability.
OmniRat™ enables developers to skip the need to humanize animal-derived antibodies before initiating preclinical pharmacokinetic evaluations of their compounds.
Dr. Roland Buelow, Founder and CEO of OMT, said: "OmniRat makes antibodies with fully human idiotypes as well as normal rats make normal rat antibodies. We look forward to making the technology available to Janssen, one of the pioneers and leaders in therapeutic human antibodies."